CN112980822B - 高催化活力的褐藻胶裂解酶突变体及其应用 - Google Patents
高催化活力的褐藻胶裂解酶突变体及其应用 Download PDFInfo
- Publication number
- CN112980822B CN112980822B CN202110230547.0A CN202110230547A CN112980822B CN 112980822 B CN112980822 B CN 112980822B CN 202110230547 A CN202110230547 A CN 202110230547A CN 112980822 B CN112980822 B CN 112980822B
- Authority
- CN
- China
- Prior art keywords
- asp
- gly
- thr
- leu
- ser
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/88—Lyases (4.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y402/00—Carbon-oxygen lyases (4.2)
- C12Y402/02—Carbon-oxygen lyases (4.2) acting on polysaccharides (4.2.2)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Enzymes And Modification Thereof (AREA)
Abstract
本发明涉及蛋白质工程技术领域,具体的说是一种高催化活力的褐藻胶裂解酶突变体及其应用。突变体为褐藻胶裂解酶AlgAT5第82位半胱氨酸、95位半胱氨酸、146位天冬氨酸、209位半胱氨酸、以及与第82位、95位或209位半胱氨酸形成氢键的氨基酸中任意一个或几个位点突变。本发明突变体或者其表达微生物能催化褐藻胶发生β消去反应制备褐藻寡糖,该方式显著提高了褐藻胶裂解酶催化效率,降低反应时间,有助于加速褐藻胶裂解酶工业化开发和应用。
Description
技术领域
本发明涉及蛋白质工程技术领域,具体的说是一种高催化活力的褐藻胶裂解酶突变体及其应用。
背景技术
褐藻胶是海洋大藻中褐藻门的藻类主要结构成分,与陆生植物的木质纤维素类似主要起到结构支撑和稳定细胞形态的作用。作为褐藻细胞中的最主要多糖成分,根据季节不同,生长周期不同,以及生长部位的不同,其含量会动态变化。褐藻胶的降解产物是褐藻寡糖,因为它具有很多优良的生物学活性,所以被广泛应用于药品、饲料添加剂、食品添加剂、植物保护等诸多领域。目前传统生产褐藻寡糖主要采用的是化学法降解,主要是利用强酸、强碱对褐藻胶进行水解,将褐藻多糖变成褐藻寡糖。然而使用传统酸法和碱法生产褐藻寡糖不仅会造成严重污染,而且降解产物的非还原端不形成不饱和的碳碳双键,因而不具备生物学活性,在实际生产应用过程中效果并不理想。与传统酸法、碱法制备生产寡糖相比,用褐藻胶裂解酶为工具酶来生产褐藻寡糖具有诸多优点,比如环保,产物具有优良的生物活性,反应过程可控等诸多优势。
然而,作为蛋白质,褐藻胶裂解酶的反应条件更加温和、反应速率平稳、反应时间较长。这导致了其在实际应用过程中存在很多问题,例如催化效率低、热稳定性差,底物特异性差,底物谱窄,这些缺点极大地限制了生物催化转化技术的应用。其中酶的催化效率作为最重要的因素之一,从根本上决定了生物催化过程能否顺利进行,更决定了其是否具有工业化应用的潜质。
为了提高酶的催化效率,随着基因工程与蛋白质工程的广泛运用,目前主要采用定向进化、半理性设计、理性设计、计算设计等方式对酶进行改造。最初的蛋白质改造过程中,由于彼时缺少蛋白结构与机理研究,突变位点的选择完全依靠研究人员的经验,适用性较窄。在此背景下,为了进一步加速蛋白质的进化,提高改造进程,定向进策略被研究人员发展出来并广泛应用于酶的设计改造,通过关键位点氨基酸的饱和突变(Saturationmutagenesis,SM)、易错PCR技术(Error-prone polymerase chain reaction,epPCR)及DNA重组(DNA shuffling)等技术,可以快速产生具有丰富随机性的突变体文库,并借用高通量筛选的方法表达并筛选特定性状提高的目标突变体,接下来从本轮突变体中筛选到目标分子在接着进行下一轮的定向进化直至达到目标要求。该技术通过对蛋白质进行多轮突变、表达和筛选,引导蛋白质的性能朝着人们需要的方向进化,从而大幅缩短蛋白质进化的过程。然而该方式耗时费力、同时不确定性太大、如果突变体库太过庞大则筛选效率定会显著降低,如果突变体库容量过小则不一定会获得目标的酶分子。因此研究人员在定向进化的基础上与理性设计结合,基于酶分子的蛋白三维结构、分子动力学模拟等再对氨基酸位点先进性一步筛选,在数目巨大的氨基酸之中筛选出关键的氨基酸位点进行研究。在理性分析计算的基础上再进行定向进化,形成了半理性设计(Semi-rational design)策略,旨在构建更接近目标的关键突变体文库,进一步提高酶的设计效率。近年来,随着结构生物学、计算生物学的迅猛发展,研究人员对蛋白质三维结构有了更进一步的深层认识,在计算机辅助的蛋白质设计出现了基于结构模拟与能量计算来进行蛋白质设计的新方法新思路,指导蛋白质改造的新思路。这被称为理性设计。
目前已知的褐藻胶酶,大多催化效率低,反应时间久,不适合大规模的工业化应用。传统方法是扩大筛选范围,特别是从高温、高压等特殊生境中寻找新型的褐藻胶裂解酶。然而该方法有多种不足,例如耗时久,盲目性高,周期长等。因此,如何利用结构分析、理性设计、分子模拟等手段,对已有的褐藻胶裂解酶进行精准的改造来获得高效的褐藻胶酶,这些手段都将会进一步加快酶分子改造的效率和准确性,为了进一步提高褐藻胶裂解酶的催化效率提供了新的路径。
发明内容
本发明目的在于提供一种高催化活力的褐藻胶裂解酶突变体及其制备。
为实现上述目的,本发明采用技术方案为:
一种高催化活力的褐藻胶裂解酶突变体,突变体为褐藻胶裂解酶AlgAT5第82位半胱氨酸、95位半胱氨酸、146位天冬氨酸、209位半胱氨酸、以及与第82位、95位或209位半胱氨酸形成氢键的氨基酸中任意一个或几个位点突变。
所述突变位点可相同或不同的突变为丙氨酸、丝氨酸或赖氨酸。
所述与第82位、95位或209位半胱氨酸形成氢键的氨基酸为第64位丝氨酸、第66位酪氨酸、第109位丝氨酸、第110位色氨酸、第111位丝氨酸、第221位苏氨酸、第222位丝氨酸中的一个或几个位点突变。
所述褐藻胶裂解酶AlgAT5第82位半胱氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第95位半胱氨酸突变为丝氨酸;所述褐藻胶裂解酶AlgAT5第146位天冬氨酸突变为赖氨酸;所述褐藻胶裂解酶AlgAT5第209位半胱氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第64位丝氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第66位酪氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第109位丝氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第110位色氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第111位丝氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第221位苏氨酸突变为丙氨酸;所述褐藻胶裂解酶AlgAT5第222位丝氨酸突变为丙氨酸。
所述突变体可为单突变,即:
所述突变体为褐藻胶裂解酶AlgAT5第82位半胱氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:7所示;
或,所述突变体为褐藻胶裂解酶AlgAT5第95位半胱氨酸突变为丝氨酸;其,氨基酸序列参见SEQ ID NO:8所示;
或,所述突变体为褐藻胶裂解酶AlgAT5第209位半胱氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:9所示;
或,所述褐藻胶裂解酶AlgAT5第64位丝氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:12所示;
或,所述褐藻胶裂解酶AlgAT5第66位酪氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:13所示;
或,所述褐藻胶裂解酶AlgAT5第109位丝氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:14所示;
或,所述褐藻胶裂解酶AlgAT5第110位色氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:15所示;
或,所述褐藻胶裂解酶AlgAT5第111位丝氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:16所示;
或,所述褐藻胶裂解酶AlgAT5第221位苏氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:18所示;
或,所述褐藻胶裂解酶AlgAT5第222位丝氨酸突变为丙氨酸;其,氨基酸序列参见SEQ ID NO:19所示;
或,所述突变体为褐藻胶裂解酶AlgAT5第146位天冬氨酸突变为赖氨酸;其,氨基酸序列参见SEQ ID NO:20所示。
所述突变体可为多突变,即:
所述突变体为褐藻胶裂解酶AlgAT5中C82A和C209A;其氨基酸序列参见SEQ IDNO:10所示;
或,所述突变体为褐藻胶裂解酶AlgAT5中C82A、C95S和C209A;其氨基酸序列参见SEQ ID NO:11所示;
或,所述突变体为褐藻胶裂解酶AlgAT5中C82A、C95S、C209A和D146K;其氨基酸序列参见SEQ ID NO:26所示;
或,所述突变体为褐藻胶裂解酶AlgAT5中C82A、C95S、S109A和C209A;其氨基酸序列参见SEQ ID NO:24所示;
或,所述突变体为褐藻胶裂解酶AlgAT5中C82A、C95S、W110A和C209A;其氨基酸序列参见SEQ ID NO:25所示;
或,所述突变体为褐藻胶裂解酶AlgAT5中C82A、C95S、C209A和S222A;其氨基酸序列参见SEQ ID NO:27所示。
一种表达载体,表达载体含所述任意一项突变体。
一种基因工程菌,基因工程菌含有所述的表达载体。
一种突变体的应用,所述突变体在催化褐藻胶发生β消去反应制备褐藻寡糖中的应用。
所述突变体在pH为5.8的0.2M的NaAC-HAC缓冲液,0.2M NaCl,1mM CaCl2,温度70℃,条件下,以褐藻胶为底物催化制备褐藻寡糖中的应用。
一种催化褐藻胶制备褐藻寡糖的方法,将所述突变体加入至褐藻胶中,在pH为5.8的0.2M的NaAC-HAC缓冲液,0.2M NaCl,1mM CaCl2,温度70℃,条件下,利用突变体催化褐藻胶发生β消去反应制备褐藻寡糖。
本发明所具有的优点:
本发明通过对蛋白晶体结构解析、分子动力学模拟、酶底物复合物分析等策略对酶的关键氨基酸位点进行了分析。其中以C82A/C95S/C209A/W110A效果最为显著,与野生型相比提高了400%以上。该突变体或者其表达微生物能催化褐藻胶发生β消去反应制备褐藻寡糖,该方式显著提高了褐藻胶裂解酶催化效率,降低反应时间,有助于加速褐藻胶裂解酶工业化开发和应用。
附图说明
图1为本发明实施例提供的AlgAT5的蛋白表达纯化结果(A)、晶体生长情况(B)及蛋白X-射线衍射(C)结果图。
图2为本发明实施例提供的lgAT5的总体结构。A,AlgAT5的结构模式图。B,计算AlgAT5表面原子的静电力。
图3为本发明实施例提供的AlgAT5-四糖复合物模型和活性中心保守氨基酸残基的分析。
图4为本发明实施例提供的基于结构的PL7家族多序列比对结果。
图5为本发明实施例提供的AlgAT5中3个非保守半胱氨酸突变体相对酶活。
图6为本发明实施例提供的多突变体C82A/C209A及C82A/C95A/C209A的酶活。
图7为本发明实施例提供的突变体C82A相对野生型的RMSF区别
图8为本发明实施例提供的突变体C95S相对野生型的RMSF区别。
图9为本发明实施例提供的突变体C209A相对野生型的RMSF区别。
图10为本发明实施例提供的与三个半胱氨酸有相互作用的氨基酸突变体酶活。
图11为本发明实施例提供的Asp146一系列突变体的酶活。
图12为本发明实施例提供的突变体D146E、D146H、D146K的pH作用范围测定。
图13为本发明实施例提供的组合突变体C82A/C95S/C209A/S109A、82A/C95S/C209A/W110A、C82A/C95S/C209A/D146K、C82A/C95S/C209A/S222A相对野生型的酶活。
具体实施方式
以下对本发明的原理和特征做进一步的描述,所列举实施例只用于解释本发明,并非用于限定本发明的保护范围。另外,下述实施例中所使用的实验方法如无特殊说明,均为本领域的常规方法。下述实施例中所用的材料、试剂等,如无特殊说明,均可从商业途径得到。
本发明基于理性设计的方法,采用蛋白晶体结构解析、分子动力学模拟、酶底物复合物分析等策略对酶的关键氨基酸位点进行了分析。使用定点突变方法改造的褐藻胶裂解酶突变体及其应用,本发明以已知热稳定性最好的褐藻胶裂解酶AlgAT5为出发酶,首先对控制底物进出区域的氨基酸进行突变加快底物进出催化孔道的速率,获得了褐藻胶裂解酶突变体C82A/C95S/C209A,氨基酸序列如SEQ ID NO:10所示,相比野生型酶催化效率提高了252%。并进一步对三个自由半胱氨酸附近的氨基酸、以及该酶活性中心氨基酸及其附近与底物结合显著相关的氨基酸残基Asp146,获得了酶活显著提高的突变体S109A、W110A、S222A和D146K,氨基酸序列如SEQ ID NO:14所示,相比野生型酶,催化效率分别提高了202.9%、238.6%、183.7%和132.3%。并进一步将突变体进行组合获得了C82A/C95S/C209A/S109A、C82A/C95S/C209A/W110A、C82A/C95S/C209A/D146K和C82A/C95S/C209A/S222A这几个组合突变体均将褐藻胶裂解酶的酶活力显著提高,与野生型相比酶活分别提高了379.8%、418.9%、342.7%和339.6%。其中以C82A/C95S/C209A/W110A效果最为显著,与野生型相比提高了400%以上。氨基酸序列如SEQ ID NO:24、SEQ ID NO:25、SEQ ID NO:26和SEQ ID NO:27所示。该突变体或者其表达微生物能催化褐藻胶发生β消去反应制备褐藻寡糖,该方式显著提高了褐藻胶裂解酶催化效率,降低反应时间,有助于加速褐藻胶裂解酶工业化开发和应用。
实施例1、对褐藻胶裂解酶AlgAT5进行晶体结构解析。
1.1蛋白表达及纯化
将海洋嗜热菌Defluviitalea phaphyphila sp.Alg1[Ji S Q,Wang B,Lu M,etal.Defluviitalea phaphyphila sp.nov.,a novel thermophilic bacterium thatdegrades brown algae[J].Applied and environmental microbiology,2016,82(3):868-877.]来源褐藻胶裂解酶AlgAT5使用pET-30a(+)载体进行蛋白表达。从37℃恒温培养箱带有卡那霉素抗性的LB中过夜培养的固体培养基平板上挑一个含有AlgAT5基因的BL21(DE3)表达菌株单克隆,在5mL的LB加卡那霉素液体培养基中200rpm,37℃过夜培养作为种子。次日将经过活化的细胞转接至500mL含有卡那霉素的LB液体培养基中,200rpm,37℃培养至OD600为0.5-0.8时,加入终浓度为1mM的IPTG,置于22-25℃恒温摇床中200rpm震荡培养16-18h,诱导蛋白的表达。
将上述获得5mL种子接种于装有250ml的LB液体培养基的500ml三角瓶中,于37℃,220rpm摇床中培养3-5小时待OD600nm达到0.8-1.2之间时,加入使用终浓度为1mM异丙基硫代半乳糖苷(IPTG)进行工程菌的诱导表达,22℃,220rpm下诱导18小时。在8,000×g、4℃条件下离心15min,收集菌体并用Buffer 0(50mM NaH2PO4,500mMNaCl,pH8.0)重悬菌体,冰水浴环境中超声破碎30-40min,破5s停5s,30%功率。在60℃水浴锅中处理10min,让大部分杂蛋白变性沉淀。在10,000×g、4℃条件下进一步离心30min,收集上清组分,破碎完成后在低温下以10000rpm离心20min,所得上清经0.22μm滤器过滤后即得到粗酶液。用Ni-NTA Resin(购自TransGen Biotech公司)对褐藻胶裂解酶粗酶液AlgAT5进行纯化。重组目的蛋白的纯化及浓缩使用蛋白质快速纯化系统对AlgAT5蛋白进行分离纯化,采用亲和层析的方式进行纯化,亲和层析柱为手动装填,柱料为Ni-NTA Resin,具体的纯化方法如下:
将诱导16-18h的菌体离心收集后,用Buffer 0(50mM NaH2PO4,300mMNaCl,pH8.0)重悬菌体。超声破碎后在10000rpm,4℃条件下离心30min,去除破碎菌体;
收集上清粗酶液,经0.22μm滤器过滤后,置于冰上备用;
依次使用5个柱体积的20%乙醇和纯化水冲洗镍柱,再用Binding buffer(20mMTris-HCl,300mM NaCl,5mM imidazole,pH8.0)冲洗镍柱直至基线平稳;
为避免非特异性结合,可以在粗酶液中加入终浓度为5mM的imidazole,然后采将上清粗酶液,用直接上样的方式穿透镍柱2-3次,流速为0.5mL/min;
上样完成后,用Binding buffer(20mM Tris-盐酸,300mM氯化钠,5mM咪唑,pH8.0)洗脱镍柱5-8个柱体积;
再用Washing buffer(20mM Tris-盐酸,300mM氯化钠,20mM咪唑,pH8.0)洗脱镍柱5-8个柱体积;
混合Washing buffer(20mM Tris-盐酸,300mM氯化钠,20mM咪唑,pH8.0)与Elution buffer(20mM Tris-HCl,0.5M NaCl,500mM咪唑,pH 8.0),从20mM到500mM的咪唑进行线性梯度洗脱,流速为0.5mL/min每2mL收集一个洗脱液,置于冰上保存;
纯化完成后,依次用Binding buffer(20mM Tris-盐酸,300mM氯化钠,5mM咪唑,pH8.0),纯化水,20%乙醇冲洗5-10个柱体积,4℃冰箱保存。
完成纯化后,用聚丙烯酰胺凝变性胶电泳检测重组褐藻胶裂解酶AlgAT5的纯化情况。且其碱基序列参见SEQ ID NO.1所示,氨基酸序列参见SEQ ID NO.2所示,蛋白纯化结果如图1A所示。结合酶活与蛋白纯度两方面因素,将聚丙烯酰胺凝变性胶电泳检测蛋白纯度达到98%以上的重组褐藻胶裂解酶AlgAT5样品装入最小分子截留量为10kD的超滤管,在4℃条件下,4000rpm离心30min,至残余体积低于1mL时,将缓冲液置换为50mM NaCl,100mM的Tris-HCl,pH8.0,每次加10mL置换buffer,共置换三次,尽可能除去咪唑。制得重组褐藻胶裂解酶AlgAT5。蛋白质浓度用BCA试剂盒测定,直至蛋白质浓度达到结晶的要求,然后将蛋白以100uL每管分装后,放入研钵用液氮速冻后,于-80℃超低温冰箱保存。重组目的蛋白浓度分析使用BCA(Thermo Fisher Scientific,USA)蛋白浓度检测试剂盒对蛋白浓度进行测定,参照BCA蛋白定量试剂盒说明书中操作步骤,进行蛋白定量。
1.2重组蛋白AlgAT5结晶及数据收集
先使用96孔板,对重组蛋白AlgAT5采用坐滴蒸汽扩散法,进行晶体初筛。初筛所用试剂来自Hampton公司的蛋白结晶试剂盒。重组蛋白AlgAT5的蛋白浓度为118.5mg/mL,筛选温度为18℃。每隔3,5天后,对晶体筛选的各个条件进行显微观察。如果长出晶体记录该条件。使用检测器ADSC Quantum 315r,在上海同步辐射装置的BL17U1束线上收集AlgAT5的X射线衍射数据。初始衍射数据集由MOSFLM处理。通过使用来自棒状杆菌的ALY-1的alyPG(PDB ID:1UAI)作为初始模型,利用分子置换方法解析三维结构。使用CCP4i软件包中的程序ARP/wARP和REFMAC5来优化启动阶段。使用获得COOT和phenix的程序进行结构的细化。使用PROCHECK评估最终模型,并将AlgAT5晶体的结构和前体晶体(AlgAT5)中的催化结构域精制至高质量。所有结构图形都是用PyMOL创建的。将蛋白质样品置于温度为16℃的结晶室中生长,每隔两天,四天,一周,两周,一个月对晶体筛选试剂盒进行观察。前一个月观察晶体生长状况,没有观察到晶体的生长。两个月之后去观察,发现在以下几个条件中观察到了蛋白晶体index 2H5,形状为薄片状;PEG/Ion 1C6、B5、A2,形状为立方块状;Crystal 2G2,形状为立方块状。2个月后在上述条件下,褐藻胶裂解酶AlgAT5在PEG/Ion Screen筛选试剂盒的0.2M Lithium chloride,20%w/v Polyethylene glycol 3,350,pH 6.8贮存液中得到了高质量的晶体,蛋白晶体生长结果如图1B所示。利用X-ray对晶体进行衍射,结果如图1C所示,对收集到的X-ray衍射数据进行整理分析,如表1所示。F32EG5晶体结构分辨率为P 21 21 21空间群,均方根偏差(RMSD)为PDB ID:5ZQI。
表1衍射数据以及修正后的主要参数。
*Numbers in parentheses refer to data in the highest resolutionshell.bRmerge=ΣhklΣi|I(hkl)i-<I(hkl)>|/ΣhklΣi<I(hkl)i>.
cRwork=(Σhkl||Fo|–|Fc||)/Σhkl|Fo|.Five percent of the data wereused for Rfree.dThe Ramachandran Plot was calculated by PROCHECK program inCCP4i program package
实施例2.基于蛋白的序列及结构分析对活性中心催化氨基酸突变研究其对AlgAT5酶活的影响
基于蛋白的序列及结构分析AlgAT5发现,该酶与PL7家族褐藻胶裂解酶的典型三维结构一样,AlgAT5也是一个β-jelly roll fold,包含两个反平行的β-折叠片层(sheet Aand sheet B)。结构包括1个α-螺旋,16个β-折叠,和2个η-螺旋。Sheet A包含了9个β-strands(β1,residues 13-16;β4,residues66-73;β7,residues 106-113;β8,residues119-125;β9,residues 128-132;β10,residues 136-142;β14,residues 182-185;andβ15,residues 187-189),sheet B包含了7个β-strands(β3,residues 48-53;β6,residues 88-95;β11,residues 151-158;β12,residues 161-166;β13,residues 169-175andβ16,residues 202-215)。余下的β-strands(β2,residues 39-41;andβ5,residues 77-79),1个α-helix(α1,residues 4-7),2个η-helices(η1,residues28-32;andη2residues193-195)与周围的loop区共同组成了AlgAT5的总体结构。
其主体结构的β-折叠片层与PL7家族的整体结构保持了一致,主要的结构差异则位于周围的可弯曲的自由loop区,这些区域共同构成了AlgAT5的催化区域如图2A所示。
根据蛋白表面的静电力的测定可以看出,这些β-折叠片层形成一个带正电的底物催化腔,蓝色显示的潜在静电表面正电荷区域,红色为负电荷和白色表示是中性区如图2B所示。催化氨基酸位点附近为白色,说明糖苷键断裂区域为电中性区。底物结合的位置用黑色虚线框表示如图2B所示。
两个酶的lid loops位于结构的中间,在图2B中用两个红色的凸起表示,与催化氨基酸一起共同组成了形成了AlgAT5的催化活性中心。
实施例3
1)基于蛋白的序列及结构分析,褐藻胶裂解酶突变体的获得:
点突变所使用的模板以质粒模板pET30a-AlgAT5。点突变的PCR反应体系如下:
正向引物(10pM) | 1μL |
反向引物(10pM) | 1μL |
模板DNA | 1μL |
2×KAPA PCR SuperMix | 50μL |
H<sub>2</sub>O | 43μL |
PCR扩增条件如下:预变性,变性,退火,延伸,循环33次,延伸。
1 | 94℃ | 10min |
2 | 94℃ | 30sec |
3 | 67℃ | 30sec |
4 | 72℃ | 6min |
5 | 72℃ | 10min |
获得不同突变体,采用的引物参见下表:
按照上述过程即获得不同突变体为:
突变体R94A是将褐藻胶裂解酶AlgAT5氨基酸序列第94位点上的精氨酸R突变成丙氨酸A,氨基酸如下SEQ ID NO:3所示。
突变体Q139A是将褐藻胶裂解酶AlgAT5氨基酸序列第139位点上的谷氨酰胺Q突变成丙氨酸A,氨基酸如下SEQ ID NO:4所示。
突变体H141A是将褐藻胶裂解酶AlgAT5氨基酸序列第141位点上的组氨酸H突变成丙氨酸A,氨基酸如下SEQ ID NO:5所示。
突变体Y216A是将褐藻胶裂解酶AlgAT5氨基酸序列第216位点上的酪氨酸Y突变成丙氨酸A,氨基酸如下SEQ ID NO:6所示。
将上述获得不同突变体PCR完成后进行琼脂糖凝胶电泳验证,为消除模板质粒的对后续转化的影响,加入Dpn I消化模板,37℃过夜处理。将突变体质粒转化到Trans1T1(全式金)待其长出单克隆后,再送样至青岛擎科测序公司使用T7的正向和反向引物进行测序验证,测序正确的菌株提取质粒转化表达菌株BL21(DE3,全式金)。突变体蛋白的表达纯化方式与实施例1记载的野生型相同。
褐藻胶裂解酶的酶活测定方法为,将上述纯化后获得褐藻胶裂解酶AlgAT5及其突变体蛋白,分别取一定量,加入到含有2g/L的海藻酸钠(Sodium Alginate)的pH5.8体系的条件下,在70℃下反应1min,在有水浴锅循环加热的紫外分光光度计下测定其OD235nm的变化值(参见表2)。一个酶活单位定义为每分钟OD235nm的值变化0.1数值。比酶活力定义为酶活与对应蛋白量的比值。相对酶活是以野生型为基准定为100%。
其中,体系为0.2M的NaAC-HAC缓冲液,0.2M NaCl,1mM CaCl2。
表2.AlgAT5及其突变体的突变体的动力学参数分析
为了研究底物与AlgAT5催化裂缝的结合,以四糖(GGMG)与AlgAT5的共结晶结构为研究对象。可以用作底物模板以鉴定AlgAT5的底物结合位置。通常,带正电荷的残基在AlgAT5的活性裂缝中具有广泛分布,形成高度正电荷区域,其用于带负电荷的多糖链结合并稳定结构多糖链的结构。另外,带正电的催化裂缝能够中和多糖链上的负电荷以帮助催化反应的发生。
根据AlgAT5中底物的结合模型,多糖链位于表面的富含电正性的空腔中(图3)。为了研究底物如何结合AlgAT5的活性位点,围绕AlgAT5-四糖中配体周围的保守催化活性位点环境的详细氨基酸残基。使用基于A1-II'结构的α-L-古洛糖醛酸和β-D-甘露糖醛酸(GGMG)的四糖计算底物结合模型。在这些模型中,我们在基板周围选择了范围内的氨基酸残基。AlgAT5中的亚位点标记为“-1”以表示结合寡糖的非还原末端的亚位点,而“+1,+2,+3”表示结合还原末端的亚位点(图3)。在酶催化反应期间,糖苷键的切割位点发生在亚点-1和+1之间(图3)。基于位于最深活动中心裂隙中的寡糖环绕中的保守残基。在亚位点-1处,糖环被残基Gln218,Arg151和Gln160识别。在亚位点+1处,糖环被残基Gln218,Arg151和Gln160识别。在亚位点+2处,糖环被残基Tyr210和Lys212识别。在亚位点+2处,糖环被残基Lys42,Gln52和Arg98识别。例如,当我们通过位点直接突变将Tyr210改为Ala210时,Y210A的酶活略低于野生型,如表2所示。
本发明所述的褐藻胶裂解酶AlgAT5的原始基因序列如SEQ ID NO.1所示。
ATGAAGGGAAGATTAAAAAAATGGTGTAGTGGCTTTCTAATTGCTATGTTAGTATCTACACCAACAGGAATGGTTAATGCAGCAAGTTTGCTTCCATCAGACATTTTAGATTTGACTAATTGGAAACTTACATTACCTATTAATGATGCAGAAGAAATTACGCAACCAGAATTAGATAGTTATGAACATAGTGAGTACTTTCATGTAAATGATGATGGAGATGCAGTCGTATTTAAAGCACACTGTGGAGGAGATACTACAGAGGGTTCTTCGTATCCAAGATGTGAACTTAGAGAAATGACAAATGATGGACAAGATAAGGCTAGTTGGTCTACTACATCTGGAACACATACTATGATAATTGATCAAAAAATCACACATCTTCCCGAAGTAAAAGACCATGTTGTTGTGGGACAAATTCATGATTCAGATGATGATGTTATAATGATTCGTTTAGAAGGAAATCATTTATTTGTAGAAGGGGATGGAGAGGAACTTGCAGATTTAGATACAGATTATGAATTAGGAACAAGATTTACTGTAAAGATAGTGGCATCCGGAGGTAAAATTAAAGTATATTATAATGGAGATTTAAAATTAACTTATAATAAGAGTGTTTCAGGATGTTATTTTAAAGCAGGTATGTATACTCAATCTAACACCAGCAAAGGTGATAGTGAGGATGCATATGGGGAAAATGAAATTTATAATCTAGTAGTAACCCATAGT
(a)序列特征:
·长度:729
·类型:基因序列
·链型:单链
·拓扑结构:线性
(b)分子类型:DNA
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的褐藻胶裂解酶AlgAT5的原始氨基酸序列如SEQ ID NO.2所示
SEQ ID NO.2:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的突变体R94A是将褐藻胶裂解酶AlgAT5氨基酸序列第94位点上的精氨酸R突变成丙氨酸A,氨基酸如下SEQ ID NO:3所示。
SEQ ID NO.3:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPACELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的突变体Q139A是将褐藻胶裂解酶AlgAT5氨基酸序列第139位点上的谷氨酰胺Q突变成丙氨酸A,氨基酸如下SEQ ID NO:4所示。
SEQ ID NO.4:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPACELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGAIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的突变体H141A是将褐藻胶裂解酶AlgAT5氨基酸序列第141位点上的组氨酸H突变成丙氨酸A,氨基酸如下SEQ ID NO:5所示。
SEQ ID NO.5:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPACELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIADSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的突变体Y216A是将褐藻胶裂解酶AlgAT5氨基酸序列第216位点上的酪氨酸Y突变成丙氨酸A,氨基酸如下SEQ ID NO:6所示。
SEQ ID NO.6:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPACELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMATQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
为了鉴定AlgAT5的催化位点使用位点直接突变来证实该结果。通过重叠PCR构建突变体,并分析它们的动力学参数。R94A,Q139A,H141A,Y216A的比酶活都小于野生型的10%。R94A,Q139A,H141A,Y216A的kcat/Km值分别为0.11,0.09,0.01和0.02,这意味着这些突变体失去其基本的承诺催化能力。R94A,Q139A,H141A,Y216A的氨基酸位点直接突变这四个残基显示出比活性和kcat的大幅下降,见表2。此外,H141A和Y216A的突变体显示出比活性最大降低。结果可能是由于几个氢键网络的断裂。证明了R94,Q139,H141,Y216对酶活是至关重要的,不可以对其进行改变。
2)同时,进一步基于分子动力学模拟分析,对Lid-loop区根部的关键氨基酸进行突变获得突变体:
按照上述记载突变过程,将引物按照下表记载进行替换,获得不同突变体:
各突变体引物
进一步获得不同突变体为:
突变体C82A是将褐藻胶裂解酶AlgAT5氨基酸序列第82位点上的半胱氨酸C突变成丙氨酸A,氨基酸如下SEQ ID NO:7所示。
突变体C95S是将褐藻胶裂解酶AlgAT5氨基酸序列第95位点上的半胱氨酸C突变成丝氨酸S,氨基酸如下SEQ ID NO:8所示。
突变体C209A是将褐藻胶裂解酶AlgAT5氨基酸序列第209位点上的半胱氨酸C突变成丙氨酸A,氨基酸如下SEQ ID NO:9所示。
本发明的突变体C82A是将褐藻胶裂解酶AlgAT5氨基酸序列第82位点上的半胱氨酸C突变成丙氨酸A,氨基酸如下SEQ ID NO:7所示。
SEQ ID NO.7:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHAGGDTTEGSSYPACELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的突变体C95S是将褐藻胶裂解酶AlgAT5氨基酸序列第95位点上的半胱氨酸C突变成丝氨酸S,氨基酸如下SEQ ID NO:8所示。
SEQ ID NO.8:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPASELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的突变体C209A是将褐藻胶裂解酶AlgAT5氨基酸序列第209位点上的半胱氨酸C突变成丙氨酸A,氨基酸如下SEQ ID NO:9所示。
SEQ ID NO.9:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPACELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGAYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
对上述进一步获得对Lid-loop区根部的关键氨基酸进行突变的突变体基于分子动力学模拟分析
根据多序列比对和二级结构预测,褐藻胶裂解酶AlgAT5具有三个非保守的半胱氨酸残基(Cys82,Cys95,Cys209),从结构上看三个半胱氨酸之间最近的距离是远大于能形成二硫键的距离。虽然这几个半胱氨酸之间没有形成二硫键,但是半胱氨酸残基的侧链-SH基团也容易和周围氨基酸形成氢键,在AlgAT5中这几个半胱氨酸的存在将会极大地限制Lid-loop区域的自由摆动幅度,引起蛋白催化效率的降低,因此我们首先进行了这三个半胱氨酸残基突变后的单突变结构进行分子动力学模拟来分析其对整体结构的影响,以及对Lid-loop区域的自由摆动幅度的作用。分子动力学模拟采用GROMACS软件完成,在343.75K条件下、不额外补加离子,只是中和电性,采用立方盒子,使用charmm36力场进行模拟,整个过程是50ns。分别构建WT和三个突变体C82A,C95S,C209A的体系进行模拟计算,结果见图7、8、9。结果发现:突变体C82A,C95S,C209A相对野生型的RMSF区别,在Lid-loop区域的摆动幅度明显都有增强,这表明三个半胱氨酸残基突变后的单突变结构对底物进出催化孔道具有正向作用,有助于提高反应的催化效率。
而后对上述进一步获得突变按照上述记载进行酶活测试(参见图5),结果显示这三个非保守半胱氨酸的突变体C82A、C95A、C209A的酶活与野生型相比分别提高了,207.5%,149.0%和178.8%,如图5所示。其原因是增大Lid-loop的摆动幅度,以此来加快底物进出催化中心的速率,达到提高酶活的目的。
实施例4、双重突变(C82A/C209A)及三重突变(C82A/C95S/C209A)的定点突变体的构建
为进一步提高野生型蛋白AlgAT5的催化活力,将三种单突变体进行了组合。定点突变的方法与实施例3中一致。以C82A为模板的基础上对第209位的半胱氨酸残基进行了突变其获得了双重突变命名为C82A/C209A,以C82A/C209A为模板对95位的半胱氨酸突变为丝氨酸S,获得了三重突变体,命名为C82A/C95S/C209A。
本发明的突变体C82A/C209A是将褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,氨基酸如下SEQ ID NO:10所示。
SEQ ID NO.10:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHAGGDTTEGSSYPACELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGAYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
本发明的突变体C82A/C95S/C209A是将褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,氨基酸如下SEQID NO:11所示。
SEQ ID NO.11:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHAGGDTTEGSSYPASELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGAYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
而后对上述进一步获得突变按照上述记载进行酶活测试(参见图6),结果显示双突变体C82A/C209A及C82A/C95A/C209A的酶活与野生型相比分别提高了,135.7%和252.0%。
实施例5、对3个自由半胱氨酸附近的氨基酸的突变提高催化效率
由上述可见这几个半胱氨酸之间没有形成二硫键,选取其与周围氨基酸形成氢键(即,半胱氨酸残基的侧链-SH基团和周围氨基酸形成氢键的氨基酸)的进一步突变。
按照上述记载突变过程,将引物按照下表记载进行替换,获得不同突变体:
进一步获得不同突变体为:
突变体S64A是将褐藻胶裂解酶AlgAT5氨基酸序列第64位点上的丝氨酸S突变成丙氨酸A,氨基酸如下SEQ ID NO:12所示。
SEQ ID NO.12:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHAEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体Y66A是将褐藻胶裂解酶AlgAT5氨基酸序列第66位点上的酪氨酸Y突变成丙氨酸A,氨基酸如下SEQ ID NO:13所示。
SEQ ID NO.13:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEAFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体S109A是将褐藻胶裂解酶AlgAT5氨基酸序列第109位点上的丝氨酸S突变成丙氨酸A,氨基酸如下SEQ ID NO:14所示。
SEQ ID NO.14:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKAAWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体W110A是将褐藻胶裂解酶AlgAT5氨基酸序列第110位点上的色氨酸W突变成丙氨酸A,氨基酸如下SEQ ID NO:15所示。
SEQ ID NO.15:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASASTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体S111A是将褐藻胶裂解酶AlgAT5氨基酸序列第111位点上的丝氨酸S突变成丙氨酸A,氨基酸如下SEQ ID NO:16所示。
SEQ ID NO.16:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWATTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体S219A是将褐藻胶裂解酶AlgAT5氨基酸序列第219位点上的丝氨酸S突变成丙氨酸A,氨基酸如下SEQ ID NO:17所示。
SEQ ID NO.17:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQANTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体T221A是将褐藻胶裂解酶AlgAT5氨基酸序列第221位点上的苏氨酸T突变成丙氨酸A,氨基酸如下SEQ ID NO:18所示。
SEQ ID NO.18:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNASKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体S222A是将褐藻胶裂解酶AlgAT5氨基酸序列第222位点上的丝氨酸S突变成丙氨酸A,氨基酸如下SEQ ID NO:19所示。
SEQ ID NO.19:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTAKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
而后对上述进一步获得突变按照上述记载进行酶活测试,结果显示,除了S219A与野生型相差不大外(97.14%)。S64A的酶活提高到野生型的140.07%、Y66A的酶活提高到野生型的130.35%、S109A的酶活提高到野生型的202.98%、W110A的酶活提高到野生型的238.58%、S111A的酶活提高到野生型的188.72%、T221A的酶活提高到野生型的163.48%、S222A的酶活提高到野生型的183.71%。其中W110A的表现最优,酶活提高到野生型的238.58%,显著的提高了催化效率。
实施例6.基于底物蛋白的结构分析对催化孔道内活性中心之外的关键氨基酸进行突变
由图3B可知,通过重点关注伸向底物海藻酸钠一侧有可能起到底物识别作用的氨基酸。比对后发现在A2-A8片层上有可能与底物结合的区域中,在+1、+2、+3位上,从A2-A5上朝向催化凹槽内侧的氨基酸基本都非常保守,最主要的区别是位于紧邻催化衷心的A6这个片层上,初步推测这个-1位是主要的底物识别位点,与酶活直接相关。进一步分析后发现146位这个天冬氨酸残基,距离最近的糖环只有同时天冬氨酸作为酸性氨基酸,其上的羧基很容易与糖环上的羟基形成氢键,而氢键是具有方向性的化学键,这一特点将会极大地影响酶与底物的结合能力,从而影响到酶的催化活力。进而对其突变获得突变体,具体为:
按照上述记载突变过程,将引物按照下述记载进行替换,获得不同突变体:
所需引物为:
D146E
Forward:5'-CAGATGATGAAGTTATAATGATTCGTTTAGAAGGAAATC-3'
Reverse:5'-TATAACTTCATCATCTGAATCATGAATTTGTCC-3'
D146K
Forward:5'-CAGATGATAAGGTTATAATGATTCGTTTAGAAGGAAATC-3'
Reverse:5'-TATAACCTTATCATCTGAATCATGAATTTGTCCC-3'
D146R
Forward:5'-CAGATGATCGTGTTATAATGATTCGTTTAGAAGGAAAT-3'
Reverse:5'-TTATAACACGATCATCTGAATCATGAATTTGTCCC-3'
D146A
Forward:5'-CAGATGATGCTGTTATAATGATTCGTTTAGAAGGAAAT-3'
Reverse:5'-TAACAGCATCATCTGAATCATGAATTTGTCC-3'
即,相应获得突变体D146A是将褐藻胶裂解酶AlgAT5氨基酸序列第146位点上的天冬氨酸D突变成丙氨酸A,氨基酸如下SEQ ID NO:20所示。
SEQ ID NO.20:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDAVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体D146E是将褐藻胶裂解酶AlgAT5氨基酸序列第146位点上的天冬氨酸D突变成谷氨酸E,氨基酸如下SEQ ID NO:21所示。
SEQ ID NO.21:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDEVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体D146K是将褐藻胶裂解酶AlgAT5氨基酸序列第146位点上的天冬氨酸D突变成赖氨酸K,氨基酸如下SEQ ID NO:22所示。
SEQ ID NO.22:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDKVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体D146R是将褐藻胶裂解酶AlgAT5氨基酸序列第146位点上的天冬氨酸D突变成精氨酸R,氨基酸如下SEQ ID NO:23所示。
SEQ ID NO.23:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHCGGDTTEGSSYPRCELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDRVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGCYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
而后对上述进一步获得突变按照上述记载进行酶活测试(参见图7),结果显示D146E的酶活降低至野生型的26.5%,D146R降低至27.7%,D146A降低至5.2%,这些结果进一步表明该氨基酸与底物催化作用直接相关,对发生催化反应有至关重要的作用。同时发现D146K将野生型酶活提高到了132.4%,这表明赖氨酸Lys在底物识别过程中起到的作用比天冬氨酸Asp146更重要,可显著提高该酶的催化效率。
通过上述对146获得突变体进一步的进行酶活测试,具体为:将上述纯化后获得褐藻胶裂解酶AlgAT5及其突变体蛋白,分别取一定量,加入到含有2g/L的海藻酸钠(SodiumAlginate)的不同pH值体系的条件下,在70℃下反应1min,在有水浴锅循环加热的紫外分光光度计下测定其OD235nm的变化值(参见图10)。一个酶活单位定义为每分钟OD235nm的值变化0.1数值。比酶活力定义为酶活与对应蛋白量的比值。相对酶活是以野生型为基准定为100%。
结果如图10所示,突变体D146E、D146H、D146K的最适pH以及pH范围都有很明显的变化。突变体D146E的最适pH变为6.5,D146H的最适pH变为7.0,适用范围是pH6-8之间,酶活保留60%以上,使用范围有明显的扩大,D146K的最适pH变为6.5,在5.0-7.0之间酶活均有70%以上。这些突变体极大地丰富了褐藻胶裂解酶的pH适用范围,使得该酶可以在多中不同pH环境下进行工作。
实施例7.组合突变体C82A/C95S/C209A/S109A、C82A/C95S/C209A/W110A、C82A/C95S/C209A/D146K、C82A/C95S/C209A/S222A的构建
为进一步提高野生型蛋白AlgAT5的催化活力,进一步将C82A/C95S/C209A和S109A、W110、D146K、AS222A和四种突变体进行了组合。定点突变的方法与实施例二中一致。
在以C82A/C95S/C209A为模板的基础上,以实施例5记载的引物,对第109、110、146、222位的氨酸残基进行了突变,获得了四重突变体,分别命名为C82A/C95S/C209A/S109A、C82A/C95S/C209A/W110A、C82A/C95S/C209A/D146K、C82A/C95S/C209A/S222A
即,获得突变体C82A/C95S/C209A/S109A是将褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第109位上的丝氨酸S突变成丙氨酸A,氨基酸序列如SEQ ID NO:24所示。
SEQ ID NO.24:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHAGGDTTEGSSYPASELREMTNDGQDKAAWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGAYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
即,获得突变体C82A/C95S/C209A/W110A是将褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第110位上的色氨酸W突变成丙氨酸A,氨基酸序列如SEQ ID NO:25所示。
SEQ ID NO.25:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHAGGDTTEGSSYPASELREMTNDGQDKASASTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGAYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
突变体C82A/C95S/C209A/D146K是将褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第146位上的天冬氨酸D突变成赖氨酸K,氨基酸序列如SEQ ID NO:26所示。
SEQ ID NO.26:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHAGGDTTEGSSYPASELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDKVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGAYFKAGMYTQSNTSKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
即,获得突变体C82A/C95S/C209A/S222A是将褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第222位上的丝氨酸S突变成丙氨酸A,氨基酸序列如SEQ ID NO:27所示。
SEQ ID NO.27:
MKGRLKKWCSGFLIAMLVSTPTGMVNAASLLPSDILDLTNWKLTLPINDAEEITQPELDSYEHSEYFHVNDDGDAVVFKAHAGGDTTEGSSYPASELREMTNDGQDKASWSTTSGTHTMIIDQKITHLPEVKDHVVVGQIHDSDDDVIMIRLEGNHLFVEGDGEELADLDTDYELGTRFTVKIVASGGKIKVYYNGDLKLTYNKSVSGAYFKAGMYTQSNTAKGDSEDAYGENEIYNLVVTHS
(a)序列特征:
·长度:243
·类型:氨基酸序列
·链型:单链
·拓扑结构:线性
(b)分子类型:蛋白质
(c)假设:否
(d)反义:否
(e)最初来源:Defluviitalea phaphyphila sp.Alg1
而后对上述进一步获得突变按照上述记载进行酶活测试(参见图13),结果显示组合突变体C82A/C95S/C209A/S109A、C82A/C95S/C209A/W110A、C82A/C95S/C209A/D146K、C82A/C95S/C209A/S222A均将褐藻胶裂解酶的酶活力显著提高,与野生型相比酶活分别提高了379.8%、418.9%、
342.7%和339.6%。其中以C82A/C95S/C209A/W110A效果最为显著,与野生型相比提高了400%以上。这几个组合突变体大大提高该酶降解褐藻胶的效率,使其具备工业化应用的实力。
序列表
<110> 中国科学院青岛生物能源与过程研究所
<120> 高催化活力的褐藻胶裂解酶突变体及其应用
<160> 27
<170> SIPOSequenceListing 1.0
<210> 1
<211> 729
<212> DNA
<213> 人工序列(Artificial Sequence)
<400> 1
atgaagggaa gattaaaaaa atggtgtagt ggctttctaa ttgctatgtt agtatctaca 60
ccaacaggaa tggttaatgc agcaagtttg cttccatcag acattttaga tttgactaat 120
tggaaactta cattacctat taatgatgca gaagaaatta cgcaaccaga attagatagt 180
tatgaacata gtgagtactt tcatgtaaat gatgatggag atgcagtcgt atttaaagca 240
cactgtggag gagatactac agagggttct tcgtatccaa gatgtgaact tagagaaatg 300
acaaatgatg gacaagataa ggctagttgg tctactacat ctggaacaca tactatgata 360
attgatcaaa aaatcacaca tcttcccgaa gtaaaagacc atgttgttgt gggacaaatt 420
catgattcag atgatgatgt tataatgatt cgtttagaag gaaatcattt atttgtagaa 480
ggggatggag aggaacttgc agatttagat acagattatg aattaggaac aagatttact 540
gtaaagatag tggcatccgg aggtaaaatt aaagtatatt ataatggaga tttaaaatta 600
acttataata agagtgtttc aggatgttat tttaaagcag gtatgtatac tcaatctaac 660
accagcaaag gtgatagtga ggatgcatat ggggaaaatg aaatttataa tctagtagta 720
acccatagt 729
<210> 2
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 3
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 3
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 4
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 4
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Ala Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 5
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 5
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile Ala Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 6
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 6
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Ala Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 7
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 7
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Ala Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 8
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 8
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Ser Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 9
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 9
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Ala Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 10
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 10
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Ala Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Ala Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 11
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 11
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Ala Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Ser Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Ala Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 12
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 12
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ala
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 13
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 13
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Ala Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 14
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 14
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ala Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 15
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 15
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Ala Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 16
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 16
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ala Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 17
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 17
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ala Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 18
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 18
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Ala Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 19
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 19
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ala Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 20
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 20
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Ala Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 21
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 21
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Glu Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 22
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 22
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Lys Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 23
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 23
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Cys Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Arg Cys Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Arg Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Cys Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 24
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 24
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Ala Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Ser Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ala Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Ala Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 25
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 25
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Ala Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Ser Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Ala Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Ala Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 26
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 26
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Ala Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Ser Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Lys Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Ala Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ser Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
<210> 27
<211> 243
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 27
Met Lys Gly Arg Leu Lys Lys Trp Cys Ser Gly Phe Leu Ile Ala Met
1 5 10 15
Leu Val Ser Thr Pro Thr Gly Met Val Asn Ala Ala Ser Leu Leu Pro
20 25 30
Ser Asp Ile Leu Asp Leu Thr Asn Trp Lys Leu Thr Leu Pro Ile Asn
35 40 45
Asp Ala Glu Glu Ile Thr Gln Pro Glu Leu Asp Ser Tyr Glu His Ser
50 55 60
Glu Tyr Phe His Val Asn Asp Asp Gly Asp Ala Val Val Phe Lys Ala
65 70 75 80
His Ala Gly Gly Asp Thr Thr Glu Gly Ser Ser Tyr Pro Ala Ser Glu
85 90 95
Leu Arg Glu Met Thr Asn Asp Gly Gln Asp Lys Ala Ser Trp Ser Thr
100 105 110
Thr Ser Gly Thr His Thr Met Ile Ile Asp Gln Lys Ile Thr His Leu
115 120 125
Pro Glu Val Lys Asp His Val Val Val Gly Gln Ile His Asp Ser Asp
130 135 140
Asp Asp Val Ile Met Ile Arg Leu Glu Gly Asn His Leu Phe Val Glu
145 150 155 160
Gly Asp Gly Glu Glu Leu Ala Asp Leu Asp Thr Asp Tyr Glu Leu Gly
165 170 175
Thr Arg Phe Thr Val Lys Ile Val Ala Ser Gly Gly Lys Ile Lys Val
180 185 190
Tyr Tyr Asn Gly Asp Leu Lys Leu Thr Tyr Asn Lys Ser Val Ser Gly
195 200 205
Ala Tyr Phe Lys Ala Gly Met Tyr Thr Gln Ser Asn Thr Ala Lys Gly
210 215 220
Asp Ser Glu Asp Ala Tyr Gly Glu Asn Glu Ile Tyr Asn Leu Val Val
225 230 235 240
Thr His Ser
Claims (5)
1.一种高催化活力的褐藻胶裂解酶突变体,其特征在于:
突变体为褐藻胶裂解酶AlgAT5氨基酸序列第82位点上的半胱氨酸C突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第95位点上的半胱氨酸C突变成丝氨酸S;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第209位点上的半胱氨酸C突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第64位点上的丝氨酸S突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第66位点上的酪氨酸Y突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第109位点上的丝氨酸S突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第110位点上的色氨酸W突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第111位点上的丝氨酸S突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第221位点上的苏氨酸T突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第222位点上的丝氨酸S突变成丙氨酸A;
或,突变体为褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A;
或,所述突变体为褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S;
或,所述突变体为褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第146位上的天冬氨酸D突变成赖氨酸K;
或,所述突变体为褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第109位上的丝氨酸S突变成丙氨酸A;
或,所述突变体为褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第110位上的色氨酸W突变成丙氨酸A;
或,所述突变体为褐藻胶裂解酶AlgAT5氨基酸序列第82和209位点上的半胱氨酸C突变成丙氨酸A,第95位半胱氨酸C突变成丝氨酸S,第222位上的丝氨酸S突变成丙氨酸A;
所述褐藻胶裂解酶AlgAT5的原始氨基酸序列如SEQ ID NO.2所示。
2.一种表达载体,其特征在于:表达载体含权利要求1所述突变体。
3.一种基因工程菌,其特征在于:基因工程菌含权利要求2所述的表达载体。
4.一种权利要求1所述的突变体的应用,其特征在于:权利要求1所述突变体在催化褐藻胶发生β消去反应制备褐藻寡糖中的应用。
5.一种催化褐藻胶制备褐藻寡糖的方法,其特征在于:将权利要求1所述突变体加入至褐藻胶中,在pH为5-8,0.1-0.3M的NaAC-HAC缓冲液,0.1-0.3 M NaCl,0.05-5mM CaCl2,温度50-80℃条件下,利用突变体催化褐藻胶发生β消去反应制备褐藻寡糖。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110230547.0A CN112980822B (zh) | 2021-03-02 | 2021-03-02 | 高催化活力的褐藻胶裂解酶突变体及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110230547.0A CN112980822B (zh) | 2021-03-02 | 2021-03-02 | 高催化活力的褐藻胶裂解酶突变体及其应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN112980822A CN112980822A (zh) | 2021-06-18 |
CN112980822B true CN112980822B (zh) | 2022-06-07 |
Family
ID=76352002
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110230547.0A Active CN112980822B (zh) | 2021-03-02 | 2021-03-02 | 高催化活力的褐藻胶裂解酶突变体及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112980822B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114908076B (zh) * | 2021-12-31 | 2023-04-07 | 潍坊麦卡阿吉生物科技有限公司 | 一种定向获得褐藻寡糖三糖产物的褐藻胶裂解酶及其应用 |
EP4273210A1 (en) * | 2022-05-04 | 2023-11-08 | The Procter & Gamble Company | Detergent compositions containing enzymes |
EP4273209A1 (en) * | 2022-05-04 | 2023-11-08 | The Procter & Gamble Company | Machine-cleaning compositions containing enzymes |
CN115948373B (zh) * | 2022-11-11 | 2023-07-25 | 深圳润康生态环境股份有限公司 | 一种褐藻胶裂解酶突变体Pl7AaM及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108929878A (zh) * | 2018-08-01 | 2018-12-04 | 中国科学院青岛生物能源与过程研究所 | 褐藻胶裂解酶的编码基因及其应用 |
CN109055343A (zh) * | 2018-09-25 | 2018-12-21 | 王存良 | 一种新型褐藻胶裂解酶AlyB10及其应用 |
CN110257361A (zh) * | 2019-07-09 | 2019-09-20 | 福州大学 | 一种褐藻胶裂解酶及其基因和应用 |
-
2021
- 2021-03-02 CN CN202110230547.0A patent/CN112980822B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108929878A (zh) * | 2018-08-01 | 2018-12-04 | 中国科学院青岛生物能源与过程研究所 | 褐藻胶裂解酶的编码基因及其应用 |
CN109055343A (zh) * | 2018-09-25 | 2018-12-21 | 王存良 | 一种新型褐藻胶裂解酶AlyB10及其应用 |
CN110257361A (zh) * | 2019-07-09 | 2019-09-20 | 福州大学 | 一种褐藻胶裂解酶及其基因和应用 |
Non-Patent Citations (1)
Title |
---|
Defluviitalea phaphyphila sp. nov., a Novel Thermophilic Bacterium That Degrades Brown Algae;Shi-Qi Ji等;《Applied and Environmental Microbiology》;20160201;第82卷(第3期);全文 * |
Also Published As
Publication number | Publication date |
---|---|
CN112980822A (zh) | 2021-06-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN112980822B (zh) | 高催化活力的褐藻胶裂解酶突变体及其应用 | |
CN111718915B (zh) | 一种烟酰胺磷酸核糖转移酶突变体、包含该突变体的重组表达载体和重组菌及应用 | |
CN108623652B (zh) | 一种蛋白质热稳定性改造的方法及其在普鲁兰酶中的应用 | |
CN108728421B (zh) | 一种羰基还原酶突变体及其用途 | |
CN113151198B (zh) | 一种γ-谷酰胺甲胺合成酶的突变体,其编码基因、氨基酸序列及其应用 | |
CN106148311A (zh) | 一种d‑阿洛酮糖‑3‑差向异构酶的突变体及其应用 | |
CN113604454B (zh) | 一种磷酸酶突变体及在催化麦芽糊精制备果糖中的应用 | |
WO2023155474A1 (zh) | meso-2,3-丁二醇脱氢酶及其突变体和应用 | |
CN111808829A (zh) | 一种γ-谷氨酰甲胺合成酶突变体及其应用 | |
CN113583997B (zh) | 一种磷酸酶突变体及在催化麦芽糊精制备甘露糖中的应用 | |
CN109097378B (zh) | 一种异戊二烯合酶和其编码基因、表达载体、工程菌以及生产异戊二烯的方法及应用 | |
CN117230051B (zh) | 一种褐藻胶裂解酶突变体Pl7MaM及其制备方法与应用 | |
CN110862980A (zh) | 一种d-阿洛酮糖3-差向异构酶突变体及其应用 | |
CN113684198A (zh) | 一种提高纤维素酶催化效率的方法及突变体5i77-m2 | |
CN113462677A (zh) | 一种α亚基突变的腈水合酶突变体及其应用 | |
CN110904088B (zh) | 耐高温d-阿洛酮糖3-差向异构酶、突变体及其应用 | |
CN112908417A (zh) | 功能序列和结构模拟相结合的基因挖掘方法、nadh偏好型草铵膦脱氢酶突变体及应用 | |
CN112980821B (zh) | 一种特异性识别底物的褐藻胶裂解酶突变体及其应用 | |
CN111394374A (zh) | 一种编码纤维素酶家族GH30的纤维素酶基因gk2691及其应用 | |
CN113122525B (zh) | 一种甲醛转化蛋白及其应用 | |
CN111057697B (zh) | 耐高温TIM barrel蛋白突变体及其应用 | |
CN114736884A (zh) | 一种胞苷单磷酸激酶突变体及其基因和应用 | |
CN109609476B (zh) | α-转氨酶和突变体及其在不对称合成L-草铵膦中的应用 | |
CN112458073A (zh) | 一种h-蛋白突变体及其应用 | |
CN106636042A (zh) | 一种热稳定性和催化活力提高的角蛋白酶突变体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |